Advances in Therapy

, 25:300 | Cite as

Role of combination therapy in the treatment of hypertension: Focus on valsartan plus amlodipine

  • Claudio Ferri
  • Giuseppe Croce
  • Giovambattista Desideri
Article

Abstract

Hypertension control is rare in clinical practice, particularly in high-risk patients. A large factor is therapeutic inertia deriving from poorly prescribed lifestyle changes, excess monotherapy use, and scarce on-treatment modifications. The use of drug combinations significantly improves blood pressure (BP) control; in particular, fixed combinations improve therapy without increasing daily pill intake, thereby favouring patient compliance and therapy continuation. The most widely used fixed combination is based on thiazide diuretics added to either angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs). Several large-scale clinical trials have been conducted showing that these combinations are effective in lowering BP. However, thiazide diuretics can reduce the metabolic benefits derived from renin-angiotensin-aldosterone system (RAAS) inhibitors in high metabolic risk patients. In contrast, ACE inhibitors or ARBs combined with dihydropyridine calcium channel antagonists (DHPCAs) exert a marked antihypertensive effect without decreasing metabolic protection by RAAS blockade. In the recent JIKEI heart study, ∼60% of patients affected by hypertension, heart failure, coronary heart disease or their combination in the valsartan arm were simultaneously treated with DHPCAs. Of note, a 39% reduction in the primary endpoint of combined morbidity and mortality was reported in the valsartan compared with the non-valsartan arm. Furthermore, in a recent multinational study, 83% of 3161 hypertensive patients treated with valsartan and the DHCPA amlodipine reported a concontrolled BP after 8 weeks of treatment. As expected, amlodipine did not negatively influence the metabolic profile of patients, thereby supporting the role of ARB+DHPCA combinations as effective and promising tools in hypertension treatment. In summary, the combination of ARBs with DHPCAs is an effective strategy in hypertension treatment through synergy between their antihypertensive and vascular protective actions, persistent metabolic benefits deriving from RAAS inhibition, and reduced incidence of side effects.

Keywords

amlodipine angiotensin-converting enzyme inhibitors angiotensin receptor antagonists dihydropyridine calcium channel antagonists hypertension treatment valsartan 

References

  1. 1.
    Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007;49:69–75.PubMedCrossRefGoogle Scholar
  2. 2.
    Cheung BM, Ong KL, Man YB, Lam KS, Lau CP. Prevalence, awareness, treatment, and control of hypertension: United States National Health and Nutrition Examination Survey 2001-2002. J Clin Hypertens. 2006;8:93–98.CrossRefGoogle Scholar
  3. 3.
    Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA. 2003;289:2363–2369.PubMedCrossRefGoogle Scholar
  4. 4.
    Volpe M, Tocci G, Trimarco B, et al. Blood pressure control in Italy: results of recent surveys on hypertension. J Hypertens. 2007;25:1491–1498.PubMedCrossRefGoogle Scholar
  5. 5.
    Weycker D, Nichols GA, O’Keeffe-Rosetti M, et al. Risk-factor clustering and cardiovascular disease risk in hypertensive patients. Am J Hypertens. 2007;20:599–607.PubMedCrossRefGoogle Scholar
  6. 6.
    Kindermann M, Adam O, Werner N, Böhm M. Clinical Trial Updates and Hotline Sessions. Presented at the European Society of Cardiology Congress 2007: (FINESSE, CARESS, OASIS 5, PRAGUE-8, OPTIMIST, GRACE, STEEPLE, SCAAR, STRATEGY, DANAMI-2, ExTRACT-TIMI-25, ISAR-REACT 2, ACUITY, ALOFT, 3CPO, PROSPECT, EVEREST, COACH, BENEFiT, MERLIN-TIMI 36, SEARCH-MI, ADVANCE, WENBIT, EUROASPIRE I-III, ARISE, getABI, RIO). Clin Res Cardiol. 2007;96:767–786.PubMedCrossRefGoogle Scholar
  7. 7.
    Elmer PJ, Obarzanek E, Vollmer WM, et al. PREMIER Collaborative Research Group. Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial. Ann Intern Med. 2006;144:485–495.PubMedGoogle Scholar
  8. 8.
    Lien LF, Brown AJ, Ard JD, et al. Effects of PREMIER lifestyle modifications on participants with and without the metabolic syndrome. Hypertension. 2007;50:609–616.PubMedCrossRefGoogle Scholar
  9. 9.
    Okonofua EC, Simpson KN, Jesri A, Rehman SU, Durkalski VL, Egan BM. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension. 2006;47:345–351.PubMedCrossRefGoogle Scholar
  10. 10.
    Guthrie B, Inkster M, Fahey T. Tackling therapeutic inertia: role of treatment data in quality indicators. BMJ. 2007;335:542–544.PubMedCrossRefGoogle Scholar
  11. 11.
    Basile J, Black HR, Flack JM, Izzo JL Jr. The role of therapeutic inertia and the use of fixed-dose combination therapy in the management of hypertension. J Clin Hypertens. 2007;9:636–645.CrossRefGoogle Scholar
  12. 12.
    Fahey T, Schroeder K, Ebrahim S. Educational and organisational interventions used to improve the management of hypertension in primary care: a systematic review. Br J Gen Pract. 2005;55:875–882.PubMedGoogle Scholar
  13. 13.
    Nesbitt SD. Antihypertensive combination therapy: optimizing blood pressure control and cardiovascular risk reduction J Clin Hypertens. 2007;9(suppl 4):26–32.Google Scholar
  14. 14.
    Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A. FEVER Study Group. The Felodipine Event Reduction (FEVER) study: a randomized long-term placebocontrolled trial in Chinese hypertensive patients. J Hypertens. 2005;23:2157–2172.PubMedCrossRefGoogle Scholar
  15. 15.
    Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829–840.PubMedCrossRefGoogle Scholar
  16. 16.
    PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033–1041.CrossRefGoogle Scholar
  17. 17.
    Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–2572.PubMedCrossRefGoogle Scholar
  18. 18.
    Mancia G, De Backer G, Dominiczak A, et al. Management of Arterial Hypertension of the European Society of Hypertension. European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105–1187.PubMedCrossRefGoogle Scholar
  19. 19.
    Dahlöf B, Devereux RB, Kjeldsen SE, et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003.PubMedCrossRefGoogle Scholar
  20. 20.
    Viberti G, Wheeldon NM. MicroAlbuminuria Reduction with VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002;106:672–678.PubMedCrossRefGoogle Scholar
  21. 21.
    Lewis EJ, Hunsicker LG, Clarke WR, et al. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–860.PubMedCrossRefGoogle Scholar
  22. 22.
    Cohn JN, Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–1675.PubMedCrossRefGoogle Scholar
  23. 23.
    Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893–1906.PubMedCrossRefGoogle Scholar
  24. 24.
    Mochizuki S, Dahlöf B, Shimizu M, et al. Heart Study Group. Valsartan in a Japanese population with hypertension and other cardiovascular disease ( JIKEI heart study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet. 2007;369:1431–1439.PubMedCrossRefGoogle Scholar
  25. 25.
    Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallelgroup studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther. 2007;29:563–580.PubMedCrossRefGoogle Scholar
  26. 26.
    Waeber B. Combination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretics in hypertension. Expert Rev Cardiovasc Ther. 2003;1:43–50.PubMedCrossRefGoogle Scholar
  27. 27.
    Pool JL, Glazer R, Weinberger M, Alvarado R, Huang J, Graff A. Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebocontrolled study followed by long-term combination therapy in hypertensive adults. Clin Ther. 2007;29:61–73.PubMedCrossRefGoogle Scholar
  28. 28.
    Bobrie G, Delonca J, Moulin C, Giacomino A, Postel-Vinay N, Asmar R. COmparative Study of efficacy of Irbesartan/HCTZ with valsartan/HCTZ using home blood pressure Monitoring in the treAtment of mild-to-moderate hypertension (COSIMA) Investigators. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations. Am J Hypertens. 2005;18:1482–1488.PubMedCrossRefGoogle Scholar
  29. 29.
    Neutel JM, Saunders E, Bakris GL, et al. INCLUSIVE Investigators. The efficacy and safety of low-and highdose fixed combinations of irbesartan/ hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. Clin Hypertens. 2005;7:578–586.CrossRefGoogle Scholar
  30. 30.
    Julius S, Kjeldsen SE, Weber M, et al. VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022–2031.PubMedCrossRefGoogle Scholar
  31. 31.
    Kjeldsen SE, Julius S, Mancia G, et al. VALUE Trial Investigators. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens. 2006;24:1405–1412.PubMedCrossRefGoogle Scholar
  32. 32.
    Aksnes TA, Kjeldsen SE, Rostrup M, Omvik P, Hua TA, Julius S. Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population. Hypertension. 2007;50:467–473.PubMedCrossRefGoogle Scholar
  33. 33.
    Voors AA. Vascular benefits of angiotensin receptor blockers. Expert Opin Investig Drugs. 2007;16:987–997.PubMedCrossRefGoogle Scholar
  34. 34.
    Lu HK, Fern RJ, Luthin D, et al. Angiotensin II stimulates T-type Ca2+ channel currents via activation of a G protein, Gi. Am J Physiol. 1996;271:C1340–C1349.PubMedGoogle Scholar
  35. 35.
    Desideri G, Bravi MC, Tucci M, et al. Angiotensin II inhibits endothelial cell motility through an AT1-dependent oxidant-sensitive decrement of nitric oxide availability. Arterioscler Thromb Vasc Biol. 2003;23:1218–1223.PubMedCrossRefGoogle Scholar
  36. 36.
    Neusser M, Tepel M, Golinski P, et al. Different calcium storage pools in vascular smooth muscle cells from spontaneously hypertensive and normotensive Wistar-Kyoto rats. J Hypertens. 1994;12:533–538.PubMedCrossRefGoogle Scholar
  37. 37.
    Carraro-Lacroix LR, Malnic G. Signaling pathways involved with the stimulatory effect of angiotensin II on vacuolar H+-ATPase in proximal tubule cells. Pflugers Arch. 2006;452:728–736.PubMedCrossRefGoogle Scholar
  38. 38.
    Fuller AJ, Hauschild BC, Gonzalez-Villalobos R, et al. Calcium and chloride channel activation by angiotensin II-AT1 receptors in preglomerular vascular smooth muscle cells. Am J Physiol Renal Physiol. 2005;289:F760–F767.PubMedCrossRefGoogle Scholar
  39. 39.
    Arun KH, Kaul CL, Ramarao P. AT1 receptors and L-type calcium channels: functional coupling in supersensitivity to angiotensin II in diabetic rats. Cardiovasc Res. 2005;65:374–386.PubMedCrossRefGoogle Scholar
  40. 40.
    de Champlain J, Karas M, Assouline L, et al. Effects of valsartan or amlodipine alone or in combination on plasma catecholamine levels at rest and during standing in hypertensive patients. J Clin Hypertens. 2007;9:168–178.CrossRefGoogle Scholar
  41. 41.
    Batenburg WW, van Esch JH, Garrelds IM, et al. Carvedilol-induced antagonismof angiotensin II: a matter of alpha1-adrenoceptor blockade. J Hypertens. 2006;24:1355–1363.PubMedCrossRefGoogle Scholar
  42. 42.
    Poldermans D, Glazes R, Kargiannis S, et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther. 2007;29:279–289.PubMedCrossRefGoogle Scholar
  43. 43.
    Brenner BM, Cooper ME, de Zeeuw D, et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869.PubMedCrossRefGoogle Scholar
  44. 44.
    Swales P, Williams B. Calcium channel blockade in combination with angiotensinconverting enzyme inhibition or angiotensin II (AT(1)-receptor) antagonism in hypertensive diabetics and patients with renal disease and hypertension. J Renin Angiotensin Aldosterone Syst. 2002;3:79–89.PubMedCrossRefGoogle Scholar
  45. 45.
    Kuschnir E, Acuña E, Sevilla D, et al. Treatment of patients with essential hypertension: amlodipine 5 mg/benazepril 20 mg compared with amlodipine 5 mg, benazepril 20 mg, and placebo. Clin Ther. 1996;18:1213–1224.PubMedCrossRefGoogle Scholar
  46. 46.
    Messerli FH, Oparil S, Feng Z. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. Am J Cardiol. 2000;86:1182–1187.PubMedCrossRefGoogle Scholar
  47. 47.
    Fogari R, Malamani GD, Zoppi A, et al. Effect of benazepril addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens. 2003;17:207–212.PubMedCrossRefGoogle Scholar
  48. 48.
    Pedrinelli R, Dell’Omo G, Melillo E, Mariani M. Amlodipine, enalapril, and dependent leg oedema in essential hypertension. Hypertension. 2000;35:621–625.PubMedGoogle Scholar
  49. 49.
    Fogari R, Zoppi A, Derosa G, et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens. 2007;21:220–224.PubMedGoogle Scholar
  50. 50.
    Pastore L, Tessitore A, Martinotti S, et al. Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo. Circulation. 1999;100:1646–1652.PubMedGoogle Scholar
  51. 51.
    Williams SA, Rayman G, Tooke JE. Dependent oedema and attenuation of postural vasoconstriction associated with nifedipine therapy for hypertension in diabetic patients. Eur J Clin Pharmacol. 1989;37:333–335.PubMedCrossRefGoogle Scholar
  52. 52.
    Iabichella ML, Dell’Omo G, Melillo E, Pedrinelli R. Calcium channel blockers blunt postural cutaneous vasoconstriction in hypertensive patients. Hypertension. 1997;29:931–937.Google Scholar
  53. 53.
    Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369:201–207.PubMedCrossRefGoogle Scholar
  54. 54.
    Atkins CE, Rausch WP, Gardner SY, Defrancesco TC, Keene BW, Levine JF. The effect of amlodipine and the combination of amlodipine and enalapril on the reninangiotensin-aldosterone system in the dog. J Vet Pharmacol Ther. 2007;30:394–400.PubMedCrossRefGoogle Scholar
  55. 55.
    Ohbayashi Y, Tsutamoto T, Sakaguchi T, et al. Effect of an angiotensin II type 1 receptor blocker, valsartan, on neurohumoral factors in patients with hypertension: comparison with a longacting calcium channel antagonist, amlodipine. J Cardiovasc Pharmacol. 2003;42(suppl 1):S71–S74.PubMedCrossRefGoogle Scholar
  56. 56.
    Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a metaanalysis. Am J Med. 2007;120:713–719.PubMedCrossRefGoogle Scholar
  57. 57.
    Malacco E, Ferri C, Grandi AM, Kilama MO, Soglian AG, Vigna L. Treatment of hypertension and adherence to treatment guidelines in clinical practice: an Italian study. Adv Ther. 2005;22:96–106.PubMedCrossRefGoogle Scholar
  58. 58.
    Wang J, Franklin SS, Safar M. Prevention of stroke and myocardial infarction by amlodipine and angiotensin receptor blockers: a quantitative overview. Hypertension. 2007;50:151–158.Google Scholar

Copyright information

© Springer Healthcare Communications 2008

Authors and Affiliations

  • Claudio Ferri
    • 1
  • Giuseppe Croce
    • 1
  • Giovambattista Desideri
    • 1
  1. 1.Department of Internal Medicine and Public HealthUniversity of L’AquilaL’AquilaItaly

Personalised recommendations